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ABSTRACT
Background and aims Nalmefene has been approved in Europe for the treatment of alcohol dependence and subse-
quently recommended by the UK National Institute for Health and Care Excellence (NICE). This study examines critically
the evidence base underpinning both decisions and the issues arising. Methods Published studies of nalmefene were
identiﬁed through a systematic search, with documents from the EuropeanMedicines Agency, theNICE appraisal and pub-
lic clinical trial registries also examined to identifymethodological issues.Results Efﬁcacy data used to support the licens-
ing of nalmefene suffer from risk of bias due to lack of speciﬁcation of a priori outcome measures and sensitivity analyses,
use of post-hoc sample reﬁnement and the use of inappropriate comparators. Despite this, evidence for the efﬁcacy of
nalmefene in reducing alcohol consumption in those with alcohol dependence is, at best, modest, and of uncertain signif-
icance to individual patients. The relevance of existing trial data to routine primary care practice is doubtful.
Conclusions Problems with the registration, design, analysis and reporting of clinical trials of nalmefene did not prevent
it being licensed and recommended for treating alcohol dependence. This creates dilemmas for primary care clinicians and
commissioning organisations where nalmefene has been heavily promoted, and poses wider questions about the effective-
ness of the medicines regulation system and how to develop the alcohol treatment evidence base.
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INTRODUCTION
Concerns about the value, analysis and reporting of phar-
maceutical industry-sponsored clinical trials are extensive
and unresolved [1–8]. Alcohol treatment trials are studies
that can be characterized by complexity operating at mul-
tiple levels, including trial design and implementation, the
nature of the problems and populations targeted, the
interventions themselves and their delivery in different
health-care settings and systems. Systematic reviews of
pharmacotherapies identify few studies at low risk of bias
[9], and it has been recommended that guidance available
in the wider clinical trials design literature on issues
such as recruitment, randomization, statistical methods
and outcome evaluation be used more effectively [10].
Problems intrinsic to this area of study are compounded
by problems in reporting, where adherence to Consolidated
Standards of Reporting Trials (CONSORT) recommenda-
tions is weak [11,12]. Conﬂicting evidence results, for
example, with large, apparently well-conducted trials pro-
ducing ﬁndings that are disappointing in light of earlier
studies [13]. This makes valid interpretation and use of
the evidence base challenging.
Nalmefene has been promoted heavily in primary
care, having been licensed in 2013 for the treatment
of alcohol dependence under unusually speciﬁc condi-
tions (see Box 1) [14]. It was recommended by the Na-
tional Institute for Health and Care Excellence (NICE)
© 2016 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction Addiction
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in late 2014 [15], and has been controversial [16–20].
The NICE appraisal committee stated that ‘the exact
magnitude of effect [of nalmefene] was uncertain’ be-
cause of ‘post hoc subgroup analyses’ in trials ‘not
powered for these analyses’ ([15], pp. 26–7). A recently
completed systematic review concluded that ‘the value
of nalmefene for treatment of alcohol addiction is not
established. At best, nalmefene has limited efﬁcacy in re-
ducing alcohol consumption’ [21]. We explore the un-
certainties in the available evidence, their regulatory
handling and vested interests involved in order to better
appreciate the issues and dilemmas arising.
THE TRIALS EVIDENCE BASE
We identiﬁed published studies on nalmefene through a sys-
tematic search (Box 2), alongside documents from the NICE
appraisal [15,22–24], the European Medicines Agency
(EMA) [14,25] and public trial registries [26–31].
Nalmefene has been the subject of six published trials, pri-
marily with people who are alcohol-dependent (Table 1).
These trials varied in treatment goals, nalmefene dose and
regimen, and the kinds of psychosocial support provided
with treatment (Table 1). The EMA assessment of nalmefene
([25], p. 28) was based primarily on three Lundbeck-
sponsored trials: Esense 1 [35,36], Esense 2 [36,37] and
Sense [38]. Two of the three other published trials [33,34],
along with three unpublished trials (Table 2), were cited as
supporting the choice of dose only ([25], p. 27). The NICE
appraisal committee assessed data from the three Lundbeck
trials because ‘post-hoc analyses’ of these studies formed the
basis of the licensed population in the marketing authoriza-
tion for nalmefene ([24], p. 26).
The Lundbeck trials (Table 1) were undertaken
together across Europe in 19 countries between 2008/09
Box 2 Search strategy.
Searches were made on 13 June 2014, supplemented by a
repeat search on 4 December 2014 to update our database
in the following:
• PubMed
• Cinahl via EBSCOHost
• HealthSource via EBSCOHost
• Web of Science Core Collection
• Google Scholar (UK)
Example search strategy (PubMed)
# Query
8 #4 OR #7
7 #5 AND #6
6 pubstatusaheadofprint OR (2013:2014[edat] OR
2013:2014[crdt] OR 2013:2014[dp])
5 alcohol* AND (nalmefene* OR selincro)
4 #3 AND Humans[Mesh]
3 #1 AND #2
2 Nalmefene OR Selincro OR nalmetrene
1 (‘Alcohol Abstinence’[Mesh] OR ‘Alcohol Deterrents’
[Mesh] OR ‘Alcohol Drinking’[Mesh] OR ‘Alcoholic
Beverages’[Mesh] OR ‘Alcoholic Intoxication’[Mesh]
OR ‘Alcoholics’[Mesh] OR ‘Alcohol-Induced Disor-
ders’[Mesh] OR ‘Alcoholism’[Mesh] OR ‘Alcohol-
Related Disorders’[Mesh] OR ‘Binge Drinking’
[Mesh]) OR alcohol*[TiAb]
Searches were made in the following online trials
registers on 3 December 2014 using the terms:
Nalmefene OR Selincro
• ClinicalTrials.gov
• European Union Clinical Trials Register
• International Standard Randomised Controlled
Trial Number register
• World Health Organization International Clinical
Trials Registry Platform
Results
n =167 records identiﬁed by database searches on
13.6.14 (dates: inception to 13.6.14)n =53 records iden-
tiﬁed by database searches on 4.12.14 (dates: 1.6.14–
4.12.14)n =8 records identiﬁed by reference chasing
Minus duplicates, a total of n=202 discrete records were
identiﬁed using the strategy above. Excluding those clearly
not relevant to nalmefene for alcohol problems from title
and abstract [58]; 144 journal articles, reports and confer-
ence abstracts were examined.
From these eight full papers [32–39] reporting from six tri-
als and one pilot trial of nalmefene for alcohol consump-
tion and 31 conference abstracts related to the same
seven trials of nalmefene (30 relating to the Esense 1,
Esense 2 and Sense trials; 1 relating to the Anton trial)
were identiﬁed.
Box 1 Marketing authorization for nalmefene [14].
Nalmefene is authorized for reducing alcohol con-
sumption:
1 in people with alcohol dependence;
2 who have a high drinking risk level (deﬁned as alco-
hol consumption of more than 60g (7.5 UK units)
per day for men and more than 40g (5 UK units)
per day for women, according to the World Health
Organization’s drinking risk levels);
3 without physical withdrawal symptoms, and who do
not require immediate detoxiﬁcation;
4 it should be initiated only in patients who continue to
have a high drinking risk level 2weeks after initial as-
sessment; and
5 only used in conjunction with continuous psychoso-
cial support focused on treatment adherence and
reducing alcohol consumption.
2 Niamh Fitzgerald et al.
© 2016 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction Addiction
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and 2010/11, and published in 2013/14. Limited infor-
mation is available on the 149 trial sites, which appear
predominantly to include specialist treatment clinics
and contract research organizations. Distributions of
trial participants by site and recruitment method (ad-
vertisements, existing clinic patients, referral) are not
reported.
Esense 1 was published ﬁrst with effects favouring
nalmefene (see Table 1), although differential dropout rates
(53% for nalmefene versus 31% for placebo) were caused
by adverse events in the nalmefene group [35]. In Esense
2 [37], a trial of identical design to Esense 1 [23], dropout
rates were approximately 41 and 38%. There are reported
reductions of approximately 65 and 60% in both alcohol
consumption outcome measures for the nalmefene group
and placebo groups, respectively, in Esense 2; an effect
favouring nalmefene was reported for one of the two mea-
sures (see Table 1) [37].
Thirty-three per cent of patients in the Esense 2 trial
were reported to have reduced their drinking during the
assessment period prior to randomization [37]. Unplanned
post-hoc analyses of data excluded these patients, and then
statistically signiﬁcant effects on both primary outcomes
were reported for the remaining ‘sub-group’ [37]. A fur-
ther 2013 report pooled this ‘sub-group’ data from both
Esense 1 and 2 trials; at 6months, the pooled nalmefene
subgroup had 3.2 [95% conﬁdence interval (CI) = –4.8 to
–1.6, P<0.0001] fewer heavy drinking days per month
and 14.3g (95% CI: –20.8 to –7.8, P<0.0001) per day
lower alcohol consumption compared with the pooled pla-
cebo subgroup [36].
The Sense trial [38] had a different design to the
Esense trials, including a 1-year treatment duration and
different primary outcomes at initial registration
(Table 3). Attrition in Sense was again high, at approxi-
mately 35% in both arms. There were no effects on efﬁ-
cacy outcomes at 6months; however, effects were
reported at 12months [38]. As for Esense 2 above, a
post-hoc subgroup analysis was conducted which ex-
cluded participants who reduced their drinking during
the assessment period prior to randomization. This anal-
ysis reported effects on both drinking outcomes after both
6 and 12months [38]. There were no differences in seri-
ous adverse events between nalmefene and placebo
groups, although the most common treatment-emergent
adverse events such as nausea, insomnia, dizziness,
vomiting, fatigue and decreased appetite were approxi-
mately twice as common in the nalmefene group, similar
to the Esense trials.
WEAKNESSES IN THE EVIDENCE BASE
Trial outcome measures were not pre-speciﬁed fully at the
outset
Clinical trial protocols should be registered publicly
[41,42], with all outcome measures and associated time-
frames speciﬁed fully to prevent selective reporting of
favourable outcomes and unacknowledged changes to
pre-speciﬁed measures [43,44]. The Lundbeck trials were
registered at www.clinicaltrials.gov [26–28] and www.
clinicaltrialsregister.eu [29–31] prior to commencement.
Amendments to the registered protocols on www.
Table 2 Available information on unpublished clinical trials.
Trial code Patient populationa Regimen & comparisona Country Outcome informationa Funders
CPH-101-0701 166 patients who ‘had a
desire to reduce and gain
better control of alcohol
consumption and
difﬁculties in controlling
drinking plus a family
history of alcohol
problems’ including some
with dependence
28w of ﬂexible dose 10/20/40mg
nalmefene or placebo taken
‘as-needed’b both with
‘biopsychosocial assessment
feedback and advice’
UK Primary outcome:
‘Monthly number
of HDD’ (heavy
drinking days)
‘75% premature
discontinuation
for nalmefene;
68% for placebo’
Biotie
CPH-101-0399 150 patients who had
‘difﬁculties in controlling
drinking’, including
some with dependence
16w of ﬁxed daily dosing
10/40mg/placebo
Finland Primary outcome:
‘Monthly number
of HDD’
Biotie
CPH-101-0400 60 patients who had
‘difﬁculties in controlling
drinking’ including some
with dependence
52-w open-label, 10/20/40mg
ﬂexible dosing, ‘as-needed’,
uncontrolled study
Finland Primary outcome:
‘Monthly number
of HDD’
Biotie
aInformation summarized or quoted (as indicated) from manufacturer’s response to request for clariﬁcation from NICE [22], pp. 14 and 16, and EMA
Assessment report [25], p. 27. Additional information is redacted in the former and no other data, including outcome data, are available publicly. bNo
information on the meaning of ‘as-needed’ in these trials is available publicly. HDD: heavy drinking days.
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Table 3 Amendments to primary outcome measures [26–28].
Trial Original primary outcomes Amendment details
SENSE (NCT00811941)
completed November 2010
18 December 2008: Amended 9 August 2011 to:
‘Measure: Safety is measured by adverse
events, clinical safety laboratory tests, vital
signs, weight, body mass index,
electrocardiograms, proﬁle of moods states
and physical examination
Time-frame: 52w
Safety issue? Yes’
‘Measure: to evaluate the long-term safety and tolerability of
as needed use of 20mg nalmefene versus placebo using
parameters such as adverse events, clinical safety laboratory
tests and vital signs
Time-frame: baseline to 52w
Safety issue? Yes
Measure: to evaluate the effect of as needed use of 20mg
nalmefene on alcohol consumption by the monthly number
of heavy drinking days (HDD)
Time-frame: baseline to 24w
Safety issue? No
Measure: to evaluate the effect of as-needed use of 20mg
nalmefene on the monthly total consumption
Time-frame: baseline to 24w
Safety issue? No’
Amended 6 August 2013 to:
‘Measure: number of patients with adverse events (AEs)
Time-frame: serious adverse events: 52w and a safety
follow-up (visit/telephone call) scheduled for 4w after
completion of the study or after withdrawal from the study.
Other adverse events: 52w
Safety issue? Yes
Description: overview of AEs
Measure: percentage of patients who withdrew due to
intolerance to treatment
Time-frame: baseline to w 52
Safety issue? Yes
Measure: change from baseline in the monthly number of
HDD
Time-frame: baseline and month 6
Safety issue? No
Description: number of HDD over a month (28 days), where
one HDD was deﬁned as a day with alcohol
consumption ≥60g for men and ≥40 g for women.
Measure: change from baseline in the monthly total alcohol
consumption (TAC)
Time-frame: baseline and month 6
Safety issue? No
Description: TAC was deﬁned as mean daily alcohol
consumption in g/day over a month (28 days)
ESENSE 1 (NCT00811720)
completed November 2010
Esense 1: 18 December 2008
Esense 2: 21 December 2008
Measure: change from baseline in the
monthly number of heavy drinking
days; change from baseline in the total
alcohol consumption
Time-frame: 24w
Safety issue? No’
Esense 1 and 2 amended 8 July 2013 to:
‘Measure: change from baseline in the monthly number of
HDD
Time-frame: baseline and month 6
Safety issue? No
Description: number of HDD over a month (28 days), where
one HDD was deﬁned as a day with alcohol
consumption ≥ 60g for men and ≥ 40g for women.
Measure: change from baseline in the monthly total alcohol
consumption (TAC)
Time-frame: baseline and month 6
Safety issue? No
Description: TAC was deﬁned as mean daily alcohol
consumption in g/day over a month (28 days)
ESENSE 2 (NCT00812461)
completed April 2011
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clinicaltrials.gov show that the efﬁcacy outcomes reported
(as above) for the Sense trial [28] were added as primary
outcomes only after trial completion (Table 3). Registered
primary outcome measures for the Esense trials were also
altered after the papers were accepted formally for publica-
tion, when deﬁnitions of ‘heavy drinking days’ and ‘total
alcohol consumption’ were added (Table 3). The European
Union (EU) register does not show trial amendment
histories.
Licensing was based on post-hoc sample reﬁnement
The licensing of nalmefene and its indication for a very
speciﬁc population (Box 1) are based on efﬁcacy data
from the unplanned subgroup analyses described above,
thus departing from the intention-to-treat principle
[45]. Subgroup analyses normally involve pre-specifying
levels of a baseline variable under investigation and test-
ing for an interaction between the treatment and those
levels, usually with a stricter level of signiﬁcance [46].
What was conducted in the nalmefene trials could be de-
scribed more accurately as post-hoc sample reﬁnement.
The information provided concerning the assessment pro-
cedures and the resulting data is not possible to evaluate
in the published reports. The deleterious effects of sample
reﬁnement at study entry are well established in this ﬁeld,
and more broadly [47]. Post-hoc sample reﬁnement
should not be regarded as anything other than
hypothesis-generating.
Sensitivity analyses do not provide consistent support for
any effect
The NICE Evidence Review Group (ERG) noted the ‘high
dropout rates in the three nalmefene studies’ ([24],
p. 66). All randomised participants should be included
in fully pre-speciﬁed [48] sensitivity analyses, even if lost
to follow-up [49]. Such analyses were not identiﬁed in
the publicly registered data [26–31]. A range of sensitiv-
ity analyses was performed none the less, of which mul-
tiple imputation (MI) is considered the least biased [50].
MI was performed in each Esense study for the two pri-
mary outcomes in both the total and subgroup popula-
tions; only one of four tests in each indicates a
treatment effect (at P<0.05) for nalmefene, and no
others come close to statistical signiﬁcance [23,35–37].
The systematic review by Palpaceur and colleagues [21]
used baseline observation carried forward and found no
evidence of beneﬁt in sensitivity analyses. Six members
of the EMA committee considering nalmefene signed a
‘Divergent Position’ statement, highlighting concerns
about efﬁcacy in light of the sensitivity analyses and the
small effect size ([25], p. 73).
Appropriate comparisons, external validity and
cost-effectiveness issues
The Declaration of Helsinki states that new interventions
must be tested against the best current proven interven-
tion, and cautions against abuse of placebo-controlled
studies [51]. In individuals with mild dependence who
have not responded to psychological intervention or who
request pharmacotherapy, naltrexone (a generic drug), in
conjunction with psychological treatment, is recom-
mended by NICE for reducing drinking [52], potentially
making this a reasonable comparator. Although placebo
comparisons have scientiﬁcmerits, and indeed are required
by the US Food and Drug Administration in these types of
studies, non-inferiority designs may also be appropriate,
depending on the precise hypotheses being tested and the
validity of the comparisons being made. Placebo run-in
periods do not inﬂuence the effects of naltrexone [53],
and placebo effect sizes in alcohol treatment trials have
been growing over time for reasons which are not under-
stood [54]. This appears to be an important target for study,
and the construct of research participation effects [55,56]
may be useful in future.
Investigators on the Lundbeck trials refer to the ‘differ-
ent biochemical proﬁle’ of nalmefene and naltrexone
[57]; however, differences in in-vitro receptor actions can-
not be assumed to be clinically important [58]. Although
naltrexone is associatedwith a risk of hepatotoxicity at very
high doses (>300mg/day), it is considered ‘very unlikely’
with doses of 25–50mg per day ([52], p. 417); the risk is
so low that routine liver function test monitoring is not rec-
ommended [52]. Thus, the clinical signiﬁcance of any dif-
ference between the two drugs is unclear. The Institute
for Quality and Efﬁciency in Healthcare (the German
equivalent of NICE) concluded that any added beneﬁt of
nalmefene over naltrexone is unproven [59]. The lack of
comparative effectiveness data prevented the NICE ERG
from commenting on the relative cost-effectiveness of
nalmefene and naltrexone [24]. Even if naltrexone plus
psychosocial support is not widely used, as the NICE
appraisal committee was informed ([15], p. 27), naltrexone
is a very similar, much cheaper drug. There is also good
evidence for acamprosate [60,61] and accumulating evi-
dence for topiramate, both also generic drugs [62].
No data are available on the adequacy of the psychoso-
cial intervention ‘BRENDA’ [40] used in both arms in the
Lundbeck trials. NICE guidelines [52] recommend more
intensive psychosocial support over 12 weekly sessions (of
cognitive–behavioural therapy, for example) in harmful
drinking and mild dependence before pharmacotherapy is
considered. A more intensive psychosocial intervention
than BRENDA would also therefore seem an appropriate
comparator, and there is a range of possible uses and com-
binations of medication and psychosocial interventions
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that could merit evaluation within more patient-centred
approaches to care [63]. The NICE ERG reported that ‘it
believes it probable that delayed [nalmefene] treatment
reserved for those who do not respond’ to this optimal sup-
port ‘is more cost-effective than immediate treatment for
all patients’ ([24], p. 118). The one published clinical trial
which used a more strongly evidence-based psychosocial
intervention (motivational enhancement therapy) found
no added beneﬁt of nalmefene [33].
DILEMMAS FOR PRACTICE AND SERVICE
COMMISSIONING
Nalmefene has not been tested in free-to-access primarycare
(in one of the early trials in Finland some participants
attended private general practices after responding to
advertisements [34]), so generalizability to UK primary care,
and similar routine practice contexts, is unknown. TheNICE
technology appraisal committee did not recommend a set-
ting for prescribing nalmefene, as such recommendations
are ‘outside the scope of a technology appraisal’ ([15],
p. 24). In the cost–effectivenessmodel provided by Lundbeck,
75% of prescribing is assumed to take place in primary care
([23], p. 218), and it has been promoted heavily there
[64,65]. In both arms of the Lundbeck trials, the ‘BRENDA’
psychosocial support consisted of an initial 30–40m session
followed by fortnightly and later monthly 15–30m sessions
([25], pp. 29–31), there have been long-standing implemen-
tation problems in primary care with much briefer interven-
tions [66,67]. The speciﬁc subgroup for whom nalmefene is
licensed may not be easy for clinicians to identify correctly
(Box 1), and it is unclear how psychosocial support will be
provided and resourced in practice. These issues also give rise
to dilemmas for commissioners of services.
Proponents of nalmefene argue that it should be used
widely and proactively for public health beneﬁt [68]; how-
ever, uncertainties about efﬁcacy, effectiveness and cost-
effectiveness of nalmefene inhibit appraisal of the possibility
of such beneﬁts. Aswith naltrexone [69], the evidence sug-
gests that any reduction in consumption may not persist
much beyond the period when nalmefene is taken [34].
The low level of conﬁdence possible in existing data
poses dilemmas for policy and practice which are not easy
to resolve. Those who look to the peer-reviewed literature
may be impressed by the variety of publications favourable
to nalmefene. However, many such pieces are authored or
co-authored by those involved in the Lundbeck trials, in re-
ceipt of Lundbeck funding or who are company employees
[68,70–82]. Others interested in the drug may access
Lundbeck literature, such as the Selincro® website for
health professionals, which emphasises absolute rather
than relative reductions in consumption among those
receiving nalmefene [83].
IS THE REGULATORY SYSTEM STRONG
ENOUGH TO HANDLE WEAK EVIDENCE?
Important weaknesses in nalmefene trial registration,
design, analysis and reporting hamper efforts to under-
stand if and how it can contribute to treating alcohol prob-
lems in general practice or elsewhere. The efﬁcacy of
nalmefene appears uncertain; a judgement of possible lim-
ited efﬁcacy in an unusually deﬁned and highly speciﬁc
post-hoc subgroup should not provide the basis for licensing
or recommending a drug.
The EMAhas been subject to criticism about its handling
of conﬂicts of interests regarding the pharmaceutical indus-
try [84] and inconsistencies in its approach to the issue of
active controls in trials [85]. In a UK Parliamentary Health
Committee enquiry into the inﬂuence of the pharmaceutical
industry, NICE acknowledged that its relationship with in-
dustry ‘is one in which some degree of conﬂict is inevitable’
([5], p. 90) and concerns exist regarding industry inﬂuence
in health technology assessment more widely [2,86]. There
is ample guidance to ensure that clinical trial ﬁndings are re-
liable, but that does not prevent such guidance being ig-
nored. The unusual nature of the evidence base available
for nalmefene, and the regulatory handling of the uncer-
tainties therein, raise difﬁcult questions about the regulatory
systems involved and the consequences arising for health-
care resource use and patient care.
IMPLICATIONS FOR ADDICTION SCIENCE
The evidence presented on nalmefene should be under-
stood in the wider context of alcohol treatment trials
[10,12]. This suggests that the existing modest effect sizes
for nalmefene [21] may reduce with further study, as has
been observed for other drugs [53,87]. Independently con-
ducted research is needed onmedications for alcohol treat-
ment, including cost–effectiveness studies and further
trials in the settings in which such treatments are used or
promoted. Further development of the evidence on psycho-
social approaches may be even more important.
Study of funding effects has not been well developed in
the addiction ﬁeld [88], despite the long-standing wider
recognition of the need for such study [89]. Such study
should be informed appropriately by existing evidence, tak-
ing care not to make unwarranted assumptions. This
investigation makes clear the need to study the involve-
ment of the pharmaceutical industry in alcohol treatment
trials and the resulting implications for the literature. Phar-
maceutical companies, including Lundbeck, are involved
in the Alcohol Clinical Trials Initiative, which aims to
improve the evidence base [10]. Effective management of
vested interests may be needed to achieve that aim, and it
is important to study the extent to which this is achieved.
8 Niamh Fitzgerald et al.
© 2016 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction Addiction
Alcohol problems are complex, and require evidence unbi-
ased by vested interests.
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